ETR:GXI

Gerresheimer (GXI) Stock Price, News & Analysis

€101.30
+2.40 (+2.43%)
(As of 04/22/2024 ET)
Today's Range
€100.00
€102.60
50-Day Range
€90.10
€110.30
52-Week Range
€81.35
€122.90
Volume
83,502 shs
Average Volume
140,925 shs
Market Capitalization
$3.50 billion
P/E Ratio
29.11
Dividend Yield
1.23%
Price Target
N/A
GXI stock logo

About Gerresheimer Stock (ETR:GXI)

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufacturing of drug delivery programs; project and quality management; and drug delivery systems, including inhalers, injection/auto injectors, pen injectors, infusion systems, and inhalation assessment, autoinjector, and other services. It also provides diagnostic and medical devices comprising point-of-care tests, laboratory disposables, chemical and technical bottles, diagnostic and polymer vials, dropper bottles, PET bottles, and medical products comprising lancing devices, infusion sets, and disposable systems. In addition, the company offers cosmetic packaging solutions, such as moulded glass flacons and jars; tubular glass ampoules, droppers, samplers and vials; and plastic packaging products, as well as pharmaceutical, laboratory, and regulatory affairs services. It offers its products to pharmacy chains, supermarkets, and wholesalers. The company serves pharma, biotech, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. Gerresheimer AG was founded in 1864 and is based in Düsseldorf, Germany.

GXI Stock Price History

GXI Stock News Headlines

Ausbruch – startet jetzt die massive FDA-Rallye?
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
BERENBERG stuft GERRESHEIMER AG auf 'Buy'
DZ BANK stuft GERRESHEIMER AG auf 'Kaufen'
Thousands of investors use this no cost solution | Do you?
In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.
Gerresheimer AG
Gerresheimer: Ist die Aktie unterbewertet?
Gerresheimer: 3. Bärenflagge in Folge!
Why Gerresheimer AG (ETR:GXI) Could Be Worth Watching
Aktueller Chart GERRESHEIMER Aktie
Aktuelle News von ratgeberGELD.at
The FTSE 100 is falling, but will it crash?
Exclusive-Telecom Italia's grid sale faces challenger plan
ECB survey sees inflation back near target by 2025
See More Headlines
Receive GXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gerresheimer and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
11,947
Year Founded
N/A

Profitability

Net Income
$116.13 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.99 billion
Cash Flow
€6.82 per share
Book Value
€41.85 per share

Miscellaneous

Free Float
N/A
Market Cap
$3.50 billion
Optionable
Not Optionable
Beta
0.90
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. Dietmar Siemssen (Age 61)
    CEO, Chairman of the Management Board and CEO of Plastics, Devices & Advanced Technologies Division
    Comp: $2.17M
  • Dr. Bernd Metzner Ph.D. (Age 54)
    CFO & Member of the Management Board
    Comp: $1.31M
  • Dr. Lukas Burkhardt (Age 45)
    Member of the Management Board
    Comp: $1.28M
  • Ms. Katja Schnitzler (Age 43)
    Global Senior VP of People & Organization and Member of Supervisory Board
    Comp: $108k
  • Mr. Guido Pickert
    Head of Investor Relations
  • Ueli Utzinger
    Group Senior Director Marketing & Communication
  • Ms. Carolin Nadilo
    Corporate Director of Investor Relations

GXI Stock Analysis - Frequently Asked Questions

How have GXI shares performed in 2024?

Gerresheimer's stock was trading at €94.35 at the start of the year. Since then, GXI shares have increased by 7.4% and is now trading at €101.30.
View the best growth stocks for 2024 here
.

Is Gerresheimer a good dividend stock?

Gerresheimer (ETR:GXI) pays an annual dividend of €1.25 per share and currently has a dividend yield of 1.18%. The dividend payout ratio is 35.92%. This payout ratio is at a healthy, sustainable level, below 75%.

What other stocks do shareholders of Gerresheimer own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gerresheimer investors own include Agilent Technologies (A), Abbott Laboratories (ABT), ACADIA Pharmaceuticals (ACAD), AxoGen (AXGN), Biohaven (BHVN), Blueprint Medicines (BPMC), Cree (CREE), Henkel AG & Co. KGaA (HEN3), Sarepta Therapeutics (SRPT) and Alcoa (AA).

This page (ETR:GXI) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners